Acumen Pharmaceuticals, Inc. (ABOS) stock
ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 2/30
$0.19−0.04 (-15.51%)
Close on Nov 18, 2026Market cap $14.06MP/E –Yield –
Acumen Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Acumen Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$87.95M. For fiscal 2025 it was -$115.54M. The highest annual figure on record is -$7.45M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$115.54M | – |
| FY2024 | Dec 31, 2024 | -$86.22M | – |
| FY2023 | Dec 31, 2023 | -$43.06M | – |
| FY2022 | Dec 31, 2022 | -$35.15M | – |
| FY2021 | Dec 31, 2021 | -$17.96M | – |
| FY2020 | Dec 31, 2020 | -$7.45M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$26.65M | – |
| Q2 FY2026 | Jun 30, 2026 | -$18.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.55M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.91M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.20M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.18M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.64M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.26M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.86M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.28M | – |
See a number that looks wrong?